173 related articles for article (PubMed ID: 19288188)
21. A tumorsphere model of glioblastoma multiforme with intratumoral heterogeneity for quantitative analysis of cellular migration and drug response.
Gudbergsson JM; Kostrikov S; Johnsen KB; Fliedner FP; Stolberg CB; Humle N; Hansen AE; Kristensen BW; Christiansen G; Kjær A; Andresen TL; Duroux M
Exp Cell Res; 2019 Jun; 379(1):73-82. PubMed ID: 30922921
[TBL] [Abstract][Full Text] [Related]
22. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.
Ogden AT; Waziri AE; Lochhead RA; Fusco D; Lopez K; Ellis JA; Kang J; Assanah M; McKhann GM; Sisti MB; McCormick PC; Canoll P; Bruce JN
Neurosurgery; 2008 Feb; 62(2):505-14; discussion 514-5. PubMed ID: 18382330
[TBL] [Abstract][Full Text] [Related]
23. Gliomasphere marker combinatorics: multidimensional flow cytometry detects CD44+/CD133+/ITGA6+/CD36+ signature.
Erhart F; Blauensteiner B; Zirkovits G; Printz D; Soukup K; Klingenbrunner S; Fischhuber K; Reitermaier R; Halfmann A; Lötsch D; Spiegl-Kreinecker S; Berger W; Visus C; Dohnal A
J Cell Mol Med; 2019 Jan; 23(1):281-292. PubMed ID: 30467961
[TBL] [Abstract][Full Text] [Related]
24. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
25. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q
Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184
[TBL] [Abstract][Full Text] [Related]
26. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
27. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Sareddy GR; Li X; Liu J; Viswanadhapalli S; Garcia L; Gruslova A; Cavazos D; Garcia M; Strom AM; Gustafsson JA; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2016 Apr; 6():24185. PubMed ID: 27126081
[TBL] [Abstract][Full Text] [Related]
28. Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin.
Jiang Y; Marinescu VD; Xie Y; Jarvius M; Maturi NP; Haglund C; Olofsson S; Lindberg N; Olofsson T; Leijonmarck C; Hesselager G; Alafuzoff I; Fryknäs M; Larsson R; Nelander S; Uhrbom L
Cell Rep; 2017 Jan; 18(4):977-990. PubMed ID: 28122246
[TBL] [Abstract][Full Text] [Related]
29. [Phenotype of SHG-44 glioma stem cell spheres and pathological characteristics of their xenograft tumors].
Wu TF; Chen JM; Chen SS; Chen GL; Wei YX; Xie XS; Du ZW; Zhou YX
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):726-31. PubMed ID: 24378091
[TBL] [Abstract][Full Text] [Related]
30. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
Silber J; Lim DA; Petritsch C; Persson AI; Maunakea AK; Yu M; Vandenberg SR; Ginzinger DG; James CD; Costello JF; Bergers G; Weiss WA; Alvarez-Buylla A; Hodgson JG
BMC Med; 2008 Jun; 6():14. PubMed ID: 18577219
[TBL] [Abstract][Full Text] [Related]
31. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma.
Kang MK; Kang SK
Stem Cells Dev; 2007 Oct; 16(5):837-47. PubMed ID: 17999604
[TBL] [Abstract][Full Text] [Related]
32. Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing.
Iwadate Y; Fujimoto S; Namba H; Yamaura A
Br J Cancer; 2003 Nov; 89(10):1896-900. PubMed ID: 14612899
[TBL] [Abstract][Full Text] [Related]
33. Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors.
Rieske P; Golanska E; Zakrzewska M; Piaskowski S; Hulas-Bigoszewska K; Wolańczyk M; Szybka M; Witusik-Perkowska M; Jaskolski DJ; Zakrzewski K; Biernat W; Krynska B; Liberski PP
BMC Cancer; 2009 Feb; 9():54. PubMed ID: 19216795
[TBL] [Abstract][Full Text] [Related]
34. Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype.
Johannessen TC; Wang J; Skaftnesmo KO; Sakariassen PØ; Enger PØ; Petersen K; Øyan AM; Kalland KH; Bjerkvig R; Tysnes BB
Neuropathol Appl Neurobiol; 2009 Aug; 35(4):380-93. PubMed ID: 19508445
[TBL] [Abstract][Full Text] [Related]
35. The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas.
Held-Feindt J; Schmelz S; Hattermann K; Mentlein R; Mehdorn HM; Sebens S
Neurochem Int; 2012 Dec; 61(7):1183-91. PubMed ID: 22948185
[TBL] [Abstract][Full Text] [Related]
36. Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines.
Harvey KA; Xu Z; Saaddatzadeh MR; Wang H; Pollok K; Cohen-Gadol AA; Siddiqui RA
J Neurosurg; 2015 Mar; 122(3):547-56. PubMed ID: 25526274
[TBL] [Abstract][Full Text] [Related]
37. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
Kelly JJ; Stechishin O; Chojnacki A; Lun X; Sun B; Senger DL; Forsyth P; Auer RN; Dunn JF; Cairncross JG; Parney IF; Weiss S
Stem Cells; 2009 Aug; 27(8):1722-33. PubMed ID: 19544433
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
Tomuleasa C; Soritau O; Kacso G; Fischer-Fodor E; Cocis A; Ioani H; Timis T; Petrescu M; Cernea D; Virag P; Irimie A; Florian IS
J BUON; 2010; 15(4):758-62. PubMed ID: 21229642
[TBL] [Abstract][Full Text] [Related]
39. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
40. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
